Pfizer Inc. (NYSE:PFE) was upgraded by investment analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating in a research report issued to clients and investors on Tuesday.

A number of other brokerages have also recently commented on PFE. Deutsche Bank AG restated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research report on Thursday, August 18th. Credit Suisse Group AG restated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Berenberg Bank set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, November 1st. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Finally, Bank of America Corp. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $37.73.

Analyst Recommendations for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.01. The firm had revenue of $13.05 billion for the quarter, compared to the consensus estimate of $13.05 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The firm’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.80%. Pfizer’s payout ratio is currently 106.20%.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/29/pfizer-inc-pfe-stock-rating-upgraded-by-barclays-plc.html.

In other Pfizer news, insider Anthony J. Maddaluna sold 10,000 shares of Pfizer stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total value of $330,000.00. Following the completion of the sale, the insider now directly owns 112,087 shares in the company, valued at $3,698,871. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Albert Bourla sold 18,390 shares of Pfizer stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $30.05, for a total value of $552,619.50. Following the completion of the sale, the insider now owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the company. Thomaspartners Inc. increased its stake in Pfizer by 4.4% in the first quarter. Thomaspartners Inc. now owns 4,814,578 shares of the biopharmaceutical company’s stock valued at $142,704,000 after buying an additional 202,518 shares in the last quarter. Mariner Wealth Advisors LLC increased its stake in Pfizer by 31.2% in the first quarter. Mariner Wealth Advisors LLC now owns 169,724 shares of the biopharmaceutical company’s stock valued at $5,031,000 after buying an additional 40,408 shares in the last quarter. Friess Associates LLC increased its stake in Pfizer by 12,154.7% in the first quarter. Friess Associates LLC now owns 443,620 shares of the biopharmaceutical company’s stock valued at $13,149,000 after buying an additional 440,000 shares in the last quarter. Wellington Management Group LLP increased its stake in Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock valued at $2,454,601,000 after buying an additional 3,936,078 shares in the last quarter. Finally, Prudential PLC increased its stake in Pfizer by 2.5% in the first quarter. Prudential PLC now owns 8,008,048 shares of the biopharmaceutical company’s stock valued at $237,359,000 after buying an additional 192,664 shares in the last quarter. Institutional investors and hedge funds own 68.53% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.